中国组织工程研究

中国组织工程研究 ›› 2011, Vol. 15 ›› Issue (52): 9760-9763.doi: 10.3969/j.issn.1673-8225.2011.52.016

• 人工假体 artificial prosthesis • 上一篇    下一篇

塞来昔布预防全髋关节置换后的异位骨化

赵伟光1，刘  利1，李晓蕾2，刘振武1   

  1. 邯郸市中心医院，1骨科，2神经内科，河北省邯郸市  056001
  • 收稿日期:2011-09-15 修回日期:2011-11-02 出版日期:2011-12-24 发布日期:2011-12-24
  • 通讯作者: 刘振武，副主任医师，邯郸市中心医院骨科，河北省邯郸市 056001
  • 作者简介:赵伟光★，男，1984年生，河北省邢台市人，汉族，硕士，医师，主要从事脊柱、关节损伤及生物力学方向的研究。 zhaoweiguang361@163.com

Celecoxib prevents against heterotopic ossification after total hip arthroplasty 

Zhao Wei-guang1, Liu Li1, Li Xiao-lei2, Liu Zhen-wu1   

  1. 1Department of Orthopaedics, 2Department of Neurology, Handan Central Hospital, Handan  056001, Hebei Province, China
  • Received:2011-09-15 Revised:2011-11-02 Online:2011-12-24 Published:2011-12-24
  • Contact: Liu Zhen-wu, Associate chief physician, Department of Orthopaedics, Handan Central Hospital, Handan 056001, Hebei Province, China
  • About author:Zhao Wei-guang★, Master, Physician, Department of Orthopaedics, Handan Central Hospital, Handan 056001, Hebei Province, China zhaoweiguang361@163.com

PDF

369

被引次数

5

摘要：

背景：目前吲哚美辛已作为预防全髋关节置换后异位骨化的常用药物，但是该药物常伴有严重不良胃肠道反应，而塞来昔布作为COX-2特异性抑制剂理论上胃肠道不良反应发生较少，但其预防全髋关节置换后异位骨化的作用目前尚缺乏研究。
目的：观察COX-2特异性抑制剂塞来昔布预防全髋关节置换后异位骨化的效果，为伴有胃肠道症状患者的临床用药提供依据。
方法：选取2010-12/2011-05行全髋关节置换患者50例，年龄55~72(65.40±3.24)岁，左髋19例，右髋31例。随机分为塞来昔布组25例和吲哚美辛组25例，分别给予塞来昔布200 mg/d或吲哚美辛75 mg/d，连续服用6周。
结果与结论：塞来昔布组异位骨化发生率为12.0%，吲哚美辛组异位骨化发生率为16.0%，两组比较差异无显著性意义(P > 0.05)。Harris髋关节功能评分优良率塞来昔布组与吲哚美辛组分别为88.0%，76.0%，两组比较差异无显著性意义(P > 0.05)。胃肠道不良反应发生率塞来昔布组和吲哚美辛组分别为16.0%，36.0%，两组比较差异有显著性意义(P=0.039)。结果可见塞来昔布预防全髋关节置换后异位骨化是可行的，并且胃肠道不良反应发生率较低。

关键词: 塞来昔布, 骨化, 异位性, 吲哚美辛, 关节成形术, 置换, 髋, 预防

Abstract:

BACKGROUND: Currently, indomethacin is commonly used in preventing heterotopic ossification after total hip arthroplasty. However, it has serious adverse gastrointestinal reactions. While celecoxib used as COX-2 specific inhibitor has less gastrointestinal side effects in theory, but its effect on prevention of heterotopic ossification after total hip arthroplasty is still unclear.
OBJECTIVE: To explore the effect of celecoxib on preventing heterotopic ossification of total hip arthroplasty patients and provide the basis for clinical medication of patients with gastrointestinal symptoms.
METHODS: Fifty patients received total hip arthroplasty from December 2010 to May 2011 were recruited into this study. The mean age was (65.40±3.24) years old, and 19 left hips and 32 right hips were involved. The patients were divided into celecoxib group and indomethacin group randomly, and were treated with celecoxib of 200 mg/d and indomethacin of 75 mg/d for 6 weeks respectively.
RESULTS AND CONCLUSION: The incidence of heterotopic ossification was 12.0% in the celecoxib group and 16.0% in the indomethacin group, and there was no significant difference between them (P > 0.05). Harris hip function scores showed the excellent and good rate was 88.0% in the celecoxib group and 76.0% in the indomethacin group, and the difference had no significance (P > 0.05). The incidences of gastrointestinal side effects in the celecoxib group and indomethacin group were 16.0% and 36.0% respectively, and the difference was significant (P=0.039). Chi-square test showed the data about adverse reaction between the two was distinctly different (P=0.039). It is indicated that the celecoxib can be used in preventing heterotopic ossification of total hip arthroplasty patients with less gastrointestinal side effects.

中图分类号: